X

Drug Profile

Mozavaptan

Alternative Names: OPC 31260; Physuline

Latest Information Update: 08 Sep 2011

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Otsuka Pharmaceutical
Class Antihypertensives; Benzazepines; Cardiotonics
Mechanism of Action Vasopressin V2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hyponatraemia

Highest Development Phases

Marketed Hyponatraemia
Discontinued Hypertension; Polycystic kidney disease; Postmyocardial infarction

Most Recent Events

21 Apr 2006 Preregistration for Hyponatraemia in Japan (unspecified route)
21 Jan 2003 OPC 31260 is now called Mozavaptan
11 Jan 2000 A preclinical study has been added to the Genitourinary Disorders pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com